Skip to content

DraconiticBiochemistryBiomolecules · Catabolism · Biosynthesis · MetabolismMap

Data

Loading the map…

Human metabolism

Reactome's human metabolism drawn as one network. Each molecule has one home node; widely shared molecules also appear as dashed copies in other territories, linked from their details. .

Territories

Select a territory to bring it forward.

Reading the map

Metabolite; its structure appears as you zoom in
Reaction, arrow toward the product
Cofactors and co-substrates are written beside the reaction when you zoom in
Dashed ring: a copy of a widely shared molecule or cofactor in another territory or pathway
Compartment transfer of the molecule it is linked to
Binding, release or complex event; its proteins are named in its details
Outline: reactions mostly in the mitochondrion

Arrows follow Reactome's curated reaction direction.

DHODH:FMN binds DHODH inhibitors

DHODH:FMN + DHODH inhibitors → DHODH:FMN:DHODH inhibitors

Reactome: R-HSA-9708759
Compartment: mitochondrial inner membrane · cytosol
Rhea: None recorded

Inputs

DHODH:FMNR-HSA-73534, mitochondrial inner membrane
DHODH inhibitorsR-ALL-9708729, cytosol

Outputs

DHODH:FMN:DHODH inhibitorsR-HSA-9708760, mitochondrial inner membrane

Literature

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase Biochemistry, 1996
Leflunomide: mode of action in the treatment of rheumatoid arthritis Ann Rheum Dis, 2000
Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis Curr Opin Investig Drugs, 2010
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2 Protein Cell, 2020
Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection Eur J Clin Invest, 2020
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial Virol Sin, 2020